Skip to main content
Tech.euFundingExplorerBeta

Ethris

Company that claims to be paving a new path from genes to therapeutic proteins using its messenger RNA technology platform

Ethris has raised €60M across 4 funding rounds from 4 investors, most recently a round in Sep 2026. Based in Bayern, Germany; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€60M
€59,666,356
Funding rounds
4
Investors
4
distinct backers
Active since
2023-01
latest 2026-09

Funding by year

EUR raised per year · 2026 YTD
Ethris — funding by year — interactive chart.
Data table
Ethris — funding by year
2023€15M
2024€4.7M
2025€10M
2026€30M

Signals

High confidence
Raise-next likelihood14
base rate 30% for Other
  • ▼ Raised very recently
  • ▲ Up-round momentum
  • ▼ Low backer re-investment
Exit likelihood23
base rate 11% (2+ rounds)
  • ▲ €30M+ raised
  • ▲ 4 rounds raised
  • ▲ Recently backed by strong-exit-track investors

Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

4 rounds
DateStageAmountInvestors
2026-09-11Other€30MEuropean Investment Bank (EIB)View deal →
2025-05-09Grant€10MEU4Health GrantView deal →
2024-06-18Other€4.7MThe Bill & Melinda Gates FoundationView deal →
2023-01-03Other€15MCipla EUView deal →

Similar companies

same sector or country

Global coverage: FundingData